Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.61 |
| ▸ | GLP1R | P43220 | 2/20 | 0.58 |
| ▸ | GCGR | P47871 | 1/20 | 0.58 |
| ▸ | GIPR | P48546 | 1/20 | 0.58 |
| ▸ | PTH1R | Q03431 | 3/20 | 0.58 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.57 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.56 |
| ▸ | CCKBR | P32239 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31719706 | 0.95 | TFPI (0.65) | TFPIVIPR1OPRL1 | |
| SCHEMBL30431350 | 0.92 | OPRL1 (0.59) | TFPIGLP1RGCGRGIPRPTH1R | |
| SCHEMBL29640388 | 0.91 | TFPI (0.65) | TFPIGLP1RGCGRGIPRPTH1R | |
| SCHEMBL31182903 | 0.90 | TFPI (0.65) | TFPIGLP1RGCGRGIPRPTH1R | |
| SCHEMBL30358174 | 0.89 | PTH1R (0.62) | GLP1RPTH1RVIPR1OPRL1CCKBR | |
| SCHEMBL29701273 | 0.88 | TFPI (0.74) | TFPIGLP1RGCGRGIPRPTH1R | |
| SCHEMBL30176428 | 0.88 | PTH1R (0.70) | TFPIGLP1RGCGRGIPRPTH1R | |
| SCHEMBL30436591 | 0.88 | VIPR1 (0.65) | TFPIGLP1RGCGRGIPRPTH1R | |
| SCHEMBL29964966 | 0.88 | PTH1R (0.62) | GLP1RPTH1RVIPR1CCKBRRXFP1 | |
| SCHEMBL30139095 | 0.88 | PTH1R (0.59) | GLP1RPTH1RVIPR1CCKBRRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250354213-A1 | METHODS RELATING TO RESPIRATORY HEALTH THERAPEUTICS | UNIV NORTHWESTERN (US) | 2025-11-20 | — | — | US | claimed |
| US-20250320559-A1 | METHODS RELATING TO IMPAIRED RESPIRATORY HEALTH THERAPEUTICS | UNIV NORTHWESTERN (US) | 2025-10-16 | — | — | US | claimed |
| US-12297227-B2 | Method for extracting target protein from biological sample and method for analyzing target protein | MEDIFORD CORPORATION (JP) | 2025-05-13 | — | — | US | claimed |
| EP-4525969-A1 | DEVICES FOR TREATING STRESS AND IMPROVING ALERTNESS USING ELECTRICAL STIMULATION | Spark Biomedical, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119604527-A | Anti-programmed death ligand 1 (PD-L1) antibodies | 安得泰医药有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119367513-A | Application of neuropeptide S in promoting EMSCs to treat spinal cord injury | 江南大学 | 2025-01-28 | — | — | CN | claimed |
| CN-119213061-A | Cross-linked protein, method for producing the same and use thereof | 纽约州立大学研究基金会 | 2024-12-27 | — | — | CN | claimed |
| EP-3440051-B1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RES TRIANGLE INST (US) | 2024-03-20 | — | — | EP | claimed |
| WO-2023224636-A1 | DEVICES FOR TREATING STRESS AND IMPROVING ALERTNESS USING ELECTRICAL STIMULATION | Spark Biomedical, Inc. (US) | 2023-11-23 | — | — | WO | claimed |
| CN-117098768-A | Biologically reactive compounds and methods of use thereof | 加利福尼亚大学董事会 | 2023-11-21 | — | — | CN | claimed |
| EP-4229639-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS Global Biopharma, Inc. (CA) | 2023-08-23 | — | — | EP | claimed |
| CN-114712484-B | Application of neuropeptide S in preparation of medicine for preventing and treating motion sickness | 中山大学 | 2023-07-04 | — | — | CN | claimed |
| EP-2981292-B1 | SUPRAMOLECULAR AGGREGATES COMPRISING A MALEIMIDO CORE | UFPEPTIDES S R L (IT) | 2022-11-02 | — | — | EP | claimed |
| US-20220237496-A1 | QUANTUM MEMORY AND ASSOCIATED APPLICATIONS | CADET, Xavier (FR) | 2022-07-28 | — | — | US | claimed |
| CN-114712484-A | Application of neuropeptide S in preparation of medicine for preventing and treating motion sickness | 中山大学 | 2022-07-08 | — | — | CN | claimed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | claimed |
| WO-2022081889-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-21 | — | — | WO | claimed |
| CN-109153635-B | Neuropeptide S receptor (NPSR) agonists | 研究三角协会 | 2022-04-08 | — | — | CN | claimed |
| EP-4739335-A1 | INTRANASAL DELIVERY | Virpax Pharmaceuticals Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20220073944-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | TRANSLATE BIO, INC. | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073944-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | NSUN3, TRDMT1, NSUN2 | TFPI 4804/4885GLP1R 3267/4885GCGR 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.